Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
Jolan Dupont,
Wesley Appermans,
Marian Dejaeger,
Isabelle Wauters,
Michaël R. Laurent,
Evelien Gielen
Affiliations
Jolan Dupont
Geriatrics and Gerontology, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium; Department of Geriatric Medicine, UZ Leuven, Leuven, Belgium; Centre for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium; Corresponding author at: Geriatrics and Gerontology, Department of Public Health and Primary Care, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Wesley Appermans
Department of Geriatric Medicine, UZ Leuven, Leuven, Belgium
Marian Dejaeger
Geriatrics and Gerontology, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium; Department of Geriatric Medicine, UZ Leuven, Leuven, Belgium; Centre for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium
Isabelle Wauters
Department of Respiratory Medicine, UZ Leuven, Leuven, Belgium
Michaël R. Laurent
Centre for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium; Imelda Hospital, Bonheiden, Belgium
Evelien Gielen
Geriatrics and Gerontology, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium; Department of Geriatric Medicine, UZ Leuven, Leuven, Belgium; Centre for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium
Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporosis but rarely reported in cancer patients with bone metastases discontinuing denosumab. We present the case of a 43-year old women with lung cancer and bone metastases who suffered multiple vertebral fractures after discontinuation of denosumab.
